This Article Free Full Text Free Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Foster, W. R. Articles by Car, B. D. Search for Related Content PubMed Articles by Foster, W. R. Articles by Car, B. D. Social Bookmarking                   What's this?

A Retrospective Analysis of Toxicogenomics in the Safety Assessment of Drug Candidates

Bristol-Myers Squibb Company, Research and Development, Princeton, New Jersey 08543, USA

Correspondence: Address correspondence to: William Foster, Bristol-Myers Squibb Co. PRI, LVL F4801C, Route 206 & Province Line Road, Princeton, NJ 08543, USA. E-mail:william.foster{at}bms.com

Toxicogenomics is considered a valuable tool for reducing pharmaceutical candidate attrition by facilitating earlier identification, prediction and understanding of toxicities. A retrospective evaluation of 3 years of routine transcriptional profiling in non-clinical safety studies was undertaken to assess the utility of toxicogenomics in drug safety assessment. Based on the analysis of studies with 33 compounds, marked global transcriptional changes (>4% transcripts at p < 0.01) were shown to be a robust biomarker for dosages considered to be toxic. In general, there was an inconsistent correlation between transcription and histopathology, most likely due to differences in sensitivity to focal microscopic lesions, to secondary effects, and to events that precede structural tissue changes. For 60% of toxicities investigated with multiple time-point data, transcriptional changes were observed prior to changes in traditional study endpoints. Candidate transcriptional markers of pharmacologic effects were detected in 40% of targets profiled. Mechanistic classification of toxicity was obtained for 30% of targets. Furthermore, data comparison to compendia of transcriptional changes provided assessments of the specificity of transcriptional responses. Overall, our experience suggests that toxicogenomics has contributed to a greater understanding of mechanisms of toxicity and to reducing drug attrition by empiric analysis where safety assessment combines toxicogenomic and traditional evaluations.

Key Words: Toxicogenomics • transcriptomics • drug safety • toxicology • microarray • biomarkers • safety biomarkers

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?